{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HPMC",
    "query": {
      "intervention": "HPMC"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 37,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HPMC&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T22:57:22.974Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01113034",
      "title": "A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma",
        "Bronchiectasis"
      ],
      "interventions": [
        {
          "name": "DAS181 dry powder, formulation F02",
          "type": "DRUG"
        },
        {
          "name": "Respitose ML006 (DMV-Fonterra)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ansun Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 11,
      "start_date": "2010-07",
      "completion_date": "2011-08-22",
      "has_results": false,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01113034"
    },
    {
      "nct_id": "NCT02569697",
      "title": "Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "HEC Placebo gel",
          "type": "OTHER"
        },
        {
          "name": "Placebo Intravaginal Ring",
          "type": "OTHER"
        },
        {
          "name": "Placebo Vaginal Film",
          "type": "OTHER"
        },
        {
          "name": "Placebo Vaginal Insert",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "CONRAD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2015-10",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-09-02",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02569697"
    },
    {
      "nct_id": "NCT01037205",
      "title": "Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "DAS181 dry powder, formulation F02",
          "type": "DRUG"
        },
        {
          "name": "Respitose ML006 (DMV-Fonterra)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ansun Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 264,
      "start_date": "2009-12",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 42,
      "location_summary": "Carmichael, California • Chula Vista, California • La Mesa, California + 39 more",
      "locations": [
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01037205"
    },
    {
      "nct_id": "NCT02831764",
      "title": "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine (3TC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 722,
      "start_date": "2016-07-18",
      "completion_date": "2022-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-12-07",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831764"
    },
    {
      "nct_id": "NCT03457727",
      "title": "GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Danirixin",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "65 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2018-03-07",
      "completion_date": "2018-07-25",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03457727"
    },
    {
      "nct_id": "NCT05686044",
      "title": "A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Buntanetap/Posiphen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annovis Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 351,
      "start_date": "2023-04-01",
      "completion_date": "2024-02-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 54,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 42 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05686044"
    },
    {
      "nct_id": "NCT03399604",
      "title": "Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "LIQ861 Inhaled Treprostinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Liquidia Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2018-01-02",
      "completion_date": "2019-11-25",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03399604"
    },
    {
      "nct_id": "NCT01336634",
      "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2011-08-05",
      "completion_date": "2021-01-07",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Orange, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336634"
    },
    {
      "nct_id": "NCT03693183",
      "title": "Efficacy Study of Ketorolac and HPMC to Treat Dry Eye",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Ketorolac/HPMC",
          "type": "DRUG"
        },
        {
          "name": "HPMC",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-03",
      "completion_date": "2009-06-15",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03693183"
    },
    {
      "nct_id": "NCT06308653",
      "title": "Psilocybin for Major Depressive Disorder (MDD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Psilocybin 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Inactive Placebo",
          "type": "DRUG"
        },
        {
          "name": "Psilocybin 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Psychosocial Support",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Usona Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 238,
      "start_date": "2024-03-13",
      "completion_date": "2027-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-03T22:57:22.974Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06308653"
    }
  ]
}